Cytek Biosciences, Inc.
CTKBHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. Valued at $596.6M, CTKB is a small-cap name in its sector. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Market Cap
$596.6M
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
23.10
EPS (TTM)
$-0.58
EPS (Fwd)
$0.20
ROE
-20.9%
ROA
-5.9%
Cash
$262.2M
Total Debt
$27.5M
Free CF
$6.4M
52W Change
47.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $262.2M in cash comfortably exceeding the $27.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $6.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -20.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $164.0M (2022) to $201.5M (2025), reflecting a 23% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cytek Biosciences, Inc.'s trajectory.